Neurocrine BiosciencesNBIX
- Legal name
- Neurocrine Biosciences, Inc.
- Sector
- Healthcare
- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- Nasdaq
Stock Price $NBIX
Latest filings
You are here#57 of 59 in Healthcare by market cap
Area = market cap · hover a tile to read it
NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.
- 8-K · Feb 5, 2016
- 10-K · Feb 11, 2016
- 8-K · Feb 11, 2016
- 10-K/A · Apr 29, 2016
- 10-Q · May 5, 2016
- 8-K · May 5, 2016
- 8-K · May 24, 2016
- 8-K · Aug 3, 2016
- 10-Q · Aug 3, 2016
- 8-K · Sep 23, 2016
- 8-K · Oct 11, 2016
- 10-Q · Nov 2, 2016
- 8-K · Nov 2, 2016
- 8-K · Dec 23, 2016
- 8-K · Jan 6, 2017
- 8-K · Feb 10, 2017
- 10-K · Feb 14, 2017
- 8-K · Feb 14, 2017
- 8-K · Mar 13, 2017
- 8-K · Apr 12, 2017
- 8-K · Apr 25, 2017
- 8-K · May 2, 2017
- 10-Q · May 9, 2017
- 8-K · May 9, 2017
- 8-K · May 24, 2017
- 8-K · Jun 9, 2017
- 8-K · Jul 5, 2017
- 8-K · Jul 12, 2017
- 10-Q · Aug 3, 2017
- 8-K · Aug 3, 2017
- 8-K/A · Sep 7, 2017
- 8-K · Oct 5, 2017
- 8-K · Oct 10, 2017
- 8-K · Oct 17, 2017
- 8-K · Oct 19, 2017
- 10-Q · Nov 1, 2017
- 8-K · Nov 1, 2017
- 8-K · Dec 5, 2017
- 8-K · Jan 8, 2018
- 8-K · Feb 9, 2018
- 10-K · Feb 13, 2018
- 8-K · Feb 13, 2018
- 8-K · Feb 14, 2018
- 8-K · Apr 30, 2018
- 10-Q · Apr 30, 2018
- 8-K · May 30, 2018
- 8-K · Jul 24, 2018
- 10-Q · Jul 31, 2018
- 8-K · Jul 31, 2018
- 8-K · Aug 3, 2018
- 8-K · Sep 24, 2018
- 8-K · Nov 5, 2018
- 10-Q · Nov 5, 2018
- 8-K · Dec 12, 2018
- 8-K · Jan 7, 2019
- 8-K · Jan 29, 2019
- 8-K · Feb 5, 2019
- 10-K · Feb 8, 2019
- 8-K · Apr 26, 2019
- 10-Q · Apr 29, 2019
- 8-K · Apr 29, 2019
- 8-K · May 23, 2019
- 8-K · Jul 29, 2019
- 10-Q · Jul 29, 2019
- 8-K · Sep 11, 2019
- 10-Q · Nov 4, 2019
- 8-K · Nov 4, 2019
- 8-K · Jan 13, 2020
- 8-K · Feb 4, 2020
- 8-K · Feb 5, 2020
- 10-K · Feb 7, 2020
- 8-K · Apr 9, 2020
- 8-K · May 6, 2020
- 10-Q · May 6, 2020
- 8-K · May 21, 2020
- 8-K · Jun 16, 2020
- 8-K · Jul 13, 2020
- 8-K · Jul 28, 2020
- 8-K · Aug 3, 2020
- 10-Q · Aug 3, 2020
- 8-K · Aug 28, 2020
- 8-K · Sep 10, 2020
- 10-Q · Nov 9, 2020
- 8-K · Nov 9, 2020
- 8-K · Nov 19, 2020
- 8-K · Nov 24, 2020
- 8-K · Jan 8, 2021
- 8-K · Feb 2, 2021
- 8-K · Feb 4, 2021
- 10-K · Feb 5, 2021
- 8-K · Apr 16, 2021
- 10-Q · May 5, 2021
- 8-K · May 5, 2021
- 8-K · May 21, 2021
- 10-Q · Aug 3, 2021
- 8-K · Aug 3, 2021
- 10-Q · Nov 1, 2021
- 8-K · Nov 1, 2021
- 8-K · Nov 22, 2021
- 8-K · Dec 23, 2021
- 8-K · Jan 6, 2022
- 8-K · Feb 11, 2022
- 10-K · Feb 11, 2022
- 8-K · May 4, 2022
- 10-Q · May 4, 2022
- 8-K · May 23, 2022
- 8-K · May 25, 2022
- 8-K · Jun 1, 2022
- 10-Q · Aug 4, 2022
- 8-K · Aug 4, 2022
- 8-K · Aug 30, 2022
- 8-K · Nov 1, 2022
- 10-Q · Nov 1, 2022
- 8-K · Jan 9, 2023
- 8-K · Feb 6, 2023
- 10-K · Feb 9, 2023
- 8-K · Feb 10, 2023
- 8-K · Feb 24, 2023
- 8-K · Mar 29, 2023
- 10-Q · May 3, 2023
- 8-K · May 3, 2023
- 8-K · May 19, 2023
- 8-K · Jul 12, 2023
- 8-K · Jul 13, 2023
- 8-K · Aug 1, 2023
- 10-Q · Aug 1, 2023
- 8-K · Sep 12, 2023
- 8-K · Oct 5, 2023
- 8-K · Oct 6, 2023
- 8-K · Oct 31, 2023
- 10-Q · Oct 31, 2023
- 8-K · Nov 9, 2023
- 8-K · Nov 13, 2023
- 8-K · Feb 7, 2024
- 10-K · Feb 9, 2024
- 10-Q · May 1, 2024
- 8-K · May 1, 2024
- 8-K · May 23, 2024
- 8-K · May 28, 2024
- 10-Q · Aug 1, 2024
- 8-K · Aug 1, 2024
- 8-K · Aug 28, 2024
- 8-K · Oct 11, 2024
- 10-Q · Oct 30, 2024
- 8-K · Oct 30, 2024
- 8-K · Nov 1, 2024
- 8-K · Dec 20, 2024
- 8-K · Jan 27, 2025
- 8-K · Feb 6, 2025
- 10-K · Feb 10, 2025
- 8-K · Apr 4, 2025
- 8-K · May 5, 2025
- 10-Q · May 5, 2025
- 8-K · May 22, 2025
- 8-K · May 30, 2025
- 10-Q · Jul 30, 2025
- 8-K · Jul 30, 2025
- 10-Q · Oct 28, 2025
- 8-K · Oct 28, 2025
- 8-K · Nov 24, 2025
- 8-K · Feb 11, 2026
- 10-K · Feb 11, 2026
- 8-K · Apr 6, 2026
- 10-Q · May 5, 2026
- 8-K · May 5, 2026
- 8-K · May 18, 2026
- 8-K · May 28, 2026
- 8-K · Jul 30, 2026
- 8-K/A · Jul 31, 2026
- 10-Q · Jul 31, 2026
- 8-K · Sep 28, 2026
- 8-K · Nov 2, 2026
- 10-Q · Nov 2, 2026
01—Key figures
Revenue Trend
Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2025
- $2.86B
3 older moves run past ±150% (largest +1034.5%); point at, tap or drag across the bars to read one.
Latest bar from 10-KFY2025Click a bar to open its SEC filingTap a bar to open its SEC filing
View full history →All NBIX Financial Metrics57 metrics
Income Statement17
Balance Sheet24
- Cash & ST Investments
- Total Assets
- Current Assets
- Cash
- Short-Term Investments
- Receivables
- Inventory
- Prepaid & Other
- PP&E
- Goodwill
- Intangibles
- Other Non-current
- Total Liabilities
- Current Liabilities
- Accounts Payable
- Accrued Liabilities
- Deferred Revenue
- Other Non-current Liab.
- Equity
- Retained Earnings
- Accumulated OCI
- APIC
- Total L&E
- Shares Outstanding
Cash Flow12
02—Overview
Neurocrine Biosciences Financial Overview 2021–2025
Updated Nov 5, 2026Net income climbed from $89.6 million in FY2021 to $478.6 milliona in FY2025, more than five times in four years, while revenue only about 2.5x'd. That gap is the story. Neurocrine has turned a one-drug franchise into a profit engine, and a second product is now pulling real weight. Earnings are scaling faster than sales, even as the company spends heavily on its pipeline.
Revenue grew from $1.13 billion in FY2021 to $2.86 billionb in FY2025. INGREZZA supplied $2.51 billion of the latest total, up from $2.31 billion in FY2024. CRENESSITY added $301.2 million in its first full year. Diluted EPS rose from $0.92 to $4.67. Reinvestment is steep: R&D reached $1.02 billion, versus $328.1 million in FY2021. Even so, operating cash flow hit $782.7 million, year-end cash and securities reached $2.54 billion, and the company repurchased $167.7 million of stock in FY2025.
At the close of FY2025, shares traded at $141.83c, or 30.4x earnings, for a market cap of $14.2 billion. Two caveats matter. Four customers account for over 90% of gross product sales. And by Q3 2026, cash and securities had dropped to $789.7 million after the $2.83 billion Soleno acquisition.
Recent Developments (Q2 and Q3 2026)
The May 2026 Soleno deal reshaped the business. VYKAT XR added $107 milliond of Q3 2026 revenue, lifting total revenue 41% to $1.12 billion. CRENESSITY more than doubled to $211 million, up 115%. INGREZZA grew 17% to $801 million, and full-year guidance rose to $2.90–$2.925 billion. GAAP EPS slipped to $1.96 from $2.04, as acquisition costs and higher R&D weighed. Non-GAAP EPS rose to $3.29 from $2.17. Eiry Roberts became Chief Medical Officer on September 28, 2026, succeeding Sanjay Keswani.
Bull case: three growth drivers, a $1.0 billione undrawn credit line, and $677.4 million of nine-month operating cash flow. Bear case: $2.2 billion of VYKAT XR intangibles face an Alvogen patent challenge and an FDA fluid-retention signal, and a Justice Department probe of INGREZZA marketing remains open. Shares traded at 31.1x trailing earnings as of the Q3 2026 report date (November 1, 2026), not today.
What to watch: VYKAT XR litigation and safety-signal developments; Q4 2026 INGREZZA sales against raised guidance
03—Filings
Recent SEC Filings
- 8-KNeurocrine Biosciences 8-K Report, Financial Results (Nov 2, 2026)Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported third-quarter 2026 financial results on November 2, 2026, with total revenues of $1,123 million, up 41% year-over-year from $795 million. INGREZZA net product sales were $801 million (up 17%), CRENESSITY net product sales were $211 million (up 115%), and VYKAT XR net product sales were $107 million. The company said net product sales exceeded $1 billion for the first time. GAAP net income was $207 million ($1.96 diluted EPS) versus $210 million ($2.04) a year earlier, while non-GAAP net income was $347 million ($3.29 diluted EPS) versus $222 million ($2.17). The company raised its full-year 2026 INGREZZA net product sales guidance to $2.90 to $2.925 billion from $2.825 to $2.875 billion. Updated full-year guidance also lowered GAAP SG&A to $1.540 to $1.560 billion from $1.575 to $1.600 billion, and raised IPR&D to $34 million from $23 million; GAAP R&D guidance was unchanged. Results reflect the May 2026 acquisition of Soleno Therapeutics, Inc., which added VYKAT XR and about $2.2 billion of related intellectual property. Cash, cash equivalents and marketable securities were approximately $790 million at September 30, 2026, compared with $2,543 million at December 31, 2025. Other developments include Phase 1 initiation for NBIP-'1968 (a GLP-1/GIP/glucagon triple agonist for obesity), a Phase 2 study of NBI-'567 for cognitive impairment in Alzheimer's disease, and the appointment of Eiry W. Roberts, M.D. as Chief Medical Officer. The company will host an R&D Day in New York on December 15, 2026. The filing furnishes the earnings release under Item 2.02, which is not deemed filed for purposes of Section 18 of the Exchange Act.
- 8-KNeurocrine Biosciences 8-K Report, Executive Changes (Sep 28, 2026)Neurocrine Biosciences, Inc. disclosed a leadership change in its executive team. Its Board of Directors appointed Eiry W. Roberts, M.D., as Chief Medical Officer, succeeding Sanjay Keswani, M.D., effective September 28, 2026. The filing states that Dr. Keswani and the Board mutually agreed that his service as Chief Medical Officer would terminate as of September 25, 2026. Dr. Keswani will be entitled to severance benefits under Section 4.1 of the Company's Executive Severance Plan, subject to the plan's terms. The Company will enter into an Amended and Restated Employment Agreement with Dr. Roberts, effective as of the transition date, which replaces his May 30, 2025 employment agreement, as amended on November 21, 2025. Under the new agreement, Dr. Roberts will receive an annual base salary of $825,000 and a target annual cash bonus equal to 60% of base pay for calendar year 2026. He will also receive equity grants under the 2025 Equity Incentive Plan with target grant values of approximately $625,000 in stock options, $250,000 in restricted stock units, and $375,000 in performance-vesting restricted stock units. The equity grants are scheduled to be made two business days after the Company files its first Form 10-Q following the transition date, provided he remains employed. Dr. Roberts' existing equity awards will remain outstanding and continue vesting under their terms. The summary in the filing is not the full agreement. The Company anticipates filing the complete Employment Agreement with its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. The filing also includes standard forward-looking statement cautions.
- 8-KNeurocrine Biosciences 8-K/A Report, Exhibit Filing (Jul 31, 2026)Neurocrine Biosciences, Inc. filed this Amendment No. 1 on Form 8-K/A to amend its May 18, 2026 Current Report, which reported the completion of its merger with Soleno Therapeutics, Inc. The amendment adds Soleno's audited consolidated financial statements for the year ended December 31, 2025 (Exhibit 99.1), its unaudited interim condensed consolidated financial statements for the three months ended March 31, 2026 (Exhibit 99.2), and unaudited pro forma condensed combined statements of income for the six months ended June 30, 2026 and the year ended December 31, 2025 (Exhibit 99.3). The filing states that it does not update any other item or discuss developments after the original report's filing date. The acquisition, completed on May 18, 2026 at a price of $53.00 per Soleno share in cash, added VYKAT XR (diazoxide choline), described as a first-in-class therapy for hyperphagia in Prader-Willi syndrome. The pro forma statements, prepared under the acquisition method with Neurocrine as the accounting acquirer, show pro forma total revenues of $1,907.5 million and net income of $294.0 million for the six months ended June 30, 2026, and total revenues of $3,050.9 million and net income of $324.5 million for 2025. Diluted pro forma earnings per share are $2.83 and $3.17, respectively. The statements exclude synergies and cost savings, and the company describes the fair value estimates as preliminary, with the purchase accounting to be finalized within one year of the closing date. Financing was provided through a May 14, 2026 credit agreement for a five-year, $1.0 billion senior secured revolving credit facility. The company drew $600.0 million on May 18, 2026 at an initial rate of 4.896% (Term SOFR plus 1.25%) and had repaid the full amount as of June 30, 2026. The filing also reports an estimated $2,237.8 million fair value for the VYKAT XR intangible asset, with a 16-year useful life, and a $168.2 million inventory fair value step-up.
- 8-KNeurocrine Biosciences 8-K Report, Financial Results (Jul 30, 2026)Neurocrine Biosciences, Inc. (NBIX) reported second-quarter 2026 total revenues of $959 million, up 39% year over year from $688 million. INGREZZA net product sales were $716 million (up 15%), CRENESSITY net product sales were $184 million (up 247% from $53 million), and VYKAT XR net product sales were $54 million, included from the May 18, 2026 closing of the Soleno Therapeutics acquisition. Unaudited pro forma total revenues including a full quarter of VYKAT XR were $998 million. GAAP net income was $144 million, or $1.39 per diluted share, compared with $108 million, or $1.06, a year earlier. Non-GAAP net income was $297 million, or $2.85 per diluted share, compared with $166 million, or $1.65. The company raised its full-year 2026 INGREZZA net product sales guidance to $2.825 billion to $2.875 billion, from $2.7 billion to $2.8 billion. It also raised GAAP R&D guidance to $1.275 billion to $1.325 billion and GAAP SG&A guidance to $1.575 billion to $1.600 billion, reflecting pipeline investment and commercial spending for the launches. The Soleno acquisition was completed in May 2026 at $53.00 per share in cash, a total equity value of $2.9 billion. Cash, cash equivalents and marketable securities totaled $482 million at June 30, 2026, down from $2,543 million at December 31, 2025. The company also entered a $1.0 billion senior secured revolving credit facility in May 2026, with the full $1.0 billion available at June 30, 2026. Management highlighted two Phase 3 readouts expected in 2027 for osavampator in major depressive disorder and direclidine in schizophrenia. The filing states that the press release is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act.
- 8-KNeurocrine Biosciences 8-K Report, Executive Changes (May 28, 2026)Neurocrine Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on May 27, 2026, with 90,118,625 of 100,581,991 eligible shares (record date March 31, 2026) present in person or by proxy. Stockholders elected three Class III Directors to terms expiring at the 2029 Annual Meeting: Kevin C. Gorman, Ph.D. (76,228,063 votes for), Gary A. Lyons (75,278,705 votes for), and Johanna Mercier (74,671,942 votes for). Continuing directors are William H. Rastetter, Ph.D., George J. Morrow, Leslie V. Norwalk, and Christine A. Poon (Class I, term expiring 2027), and Kyle W. Gano, Ph.D., Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D. (Class II, term expiring 2028). Stockholders also approved, on an advisory basis, the compensation paid to the company's named executive officers (78,993,894 for, 5,669,155 against, 103,231 abstentions). They approved the amendment of the 2025 Equity Incentive Plan (the "Amended 2025 Plan") with 79,131,622 votes for and 5,568,926 against. A summary of the Amended 2025 Plan's material terms appears in the definitive proxy statement filed April 15, 2026, which is incorporated by reference. Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 83,880,185 votes for and 6,170,483 against. This filing reports routine annual meeting outcomes, with no material change to officers or directors disclosed.
04—See also
Related Companies
Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.